Who are MEDI4736's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): AVELUMAB, DURVALUMAB, Pf-06823859, Atezolizumab Injection [Tecentriq], Cisplatin / Carboplatin，Gemcitabine，Cindilimab, AB.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/medi4736.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

MEDI4736 — Competitive Intelligence Brief

MEDI4736 (MEDI4736) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: PD-L1 inhibitor. Area: Oncology.

phase 3 PD-L1 inhibitor PD-L1 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

MEDI4736 (MEDI4736) — MedImmune LLC. MEDI4736 is a monoclonal antibody that blocks PD-L1, preventing its interaction with PD-1 and PD-L2 receptors to enhance anti-tumor immune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MEDI4736 TARGET	MEDI4736	MedImmune LLC	phase 3	PD-L1 inhibitor	PD-L1
AVELUMAB	AVELUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
DURVALUMAB	DURVALUMAB		marketed	Programmed Death Ligand-1 Blocker [EPC]	PD-L1	2017-01-01
Pf-06823859	pf-06823859	Pfizer	marketed	Monoclonal Antibody	PD-1/PD-L1
Atezolizumab Injection [Tecentriq]	Atezolizumab Injection [Tecentriq]	Nykode Therapeutics ASA	marketed	PD-L1 inhibitor	PD-L1
Cisplatin / Carboplatin，Gemcitabine，Cindilimab	Cisplatin / Carboplatin，Gemcitabine，Cindilimab	People's Hospital of Quzhou	marketed	Combination chemotherapy with immune checkpoint inhibitor	DNA (platinum agents, gemcitabine); PD-L1 (cindilimab)
AB	AB	GlaxoSmithKline	marketed	PD-L1 inhibitor	PD-L1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (PD-L1 inhibitor class)

Biocad · 13 drugs in this class
Shanghai Henlius Biotech · 8 drugs in this class
Celltrion · 5 drugs in this class
Mabwell (Shanghai) Bioscience Co., Ltd. · 4 drugs in this class
AstraZeneca · 4 drugs in this class
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · 2 drugs in this class
Innovent Biologics (Suzhou) Co. Ltd. · 2 drugs in this class
Jiangsu HengRui Medicine Co., Ltd. · 2 drugs in this class
Shanghai Hengrui Pharmaceutical Co., Ltd. · 2 drugs in this class
CStone Pharmaceuticals · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MEDI4736 — Competitive Intelligence Brief. https://druglandscape.com/ci/medi4736. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab